Condition: Solid Tumor · Sponsor: Oxford BioTherapeutics Ltd
The purpose of this study is to evaluate OBT076, which is a drug that combines an antibody with an anti-cancer drug. This class of drugs are called Antibody-Drug Conjugates (ADC). Antibodies are normally produced in the human body by the immune system to fight infections but can be designed to target cancer cells and deliver an anti-cancer drug. OBT076 is composed of an antibody that targets the CD205 protein on cancer cells and delivers an anti-cancer drug which can kill them. OBT076 is an "Investigational Drug", which means that it is still being studied and has not yet been approved by the US Food and Drug Administration (FDA), the European Medicines Agency (EMA) or any other regulatory authorities to be prescribed by doctors for the treatment of metastatic or recurrent solid tumors. The use of OBT076 in this study is investigational. This is a Phase I research study designed to look at several dose levels of the study drug to find the highest dose level that is safe and well-tolerated (does not cause unacceptable side effects), and to examine the effects of the study drug in a small group of research participants. The study will also look at the effectiveness of OBT076 as an anti-cancer therapy. Once the optimal dose is determined and safety is assessed, additional research participants will be treated at the optimal dose level to further evaluate safety and effectiveness.
This description comes directly from the study's public registry record.
Medical Monitor · +44 (0)1235 861770 · OBT076-001@oxfordbiotherapeutics.com
Always discuss trial participation with your own doctor first.
| Mayo Clinic | Phoenix, Arizona, United States | Completed |
| Cedars-Sinai | Los Angeles, California, United States | Completed |
| UCLA | Santa Monica, California, United States | Completed |
| Moffitt Cancer Center | Tampa, Florida, United States | Completed |
| The State University of Iowa | Iowa City, Iowa, United States | Active Not Recruiting |
| St. Elizabeth Healthcare | Edgewood, Kentucky, United States | Completed |
| University of Mississippi Medical Center | Jackson, Mississippi, United States | Completed |
| Quantum Santa Fe | Santa Fe, New Mexico, United States | Completed |
| Columbia University Medical Center | New York, New York, United States | Completed |
| University of Pittsburgh | Pittsburgh, Pennsylvania, United States | Completed |
| Institut Jules Bordet | Brussels, Belgium | Recruiting |
| AZ Groeninge | Kortrijk, Belgium | Completed |
+ 15 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04064359